Servier Drug Patent Portfolio

Servier owns 2 orange book drugs protected by 14 US patents Given below is the list of Servier's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10980788 Therapy for treating malignancies 07 Jun, 2039
Active
US11345677 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same 16 Jan, 2039
Active
US10653710 Combination therapy for treating malignancies 18 Oct, 2036
Active
US11844758 Therapeutically active compounds and their methods of use 04 Dec, 2035
Active
US10449184 Pharmaceutical compositions of therapeutically active compounds 13 Mar, 2035
Active
US10799490 Pharmaceutical compositions of therapeutically active compounds 13 Mar, 2035
Active
US9968595 Pharmaceutical compositions of therapeutically active compounds 13 Mar, 2035
Active
US10172864 Therapeutically active compounds and their methods of use 11 Jul, 2034
Active
US9579324 Therapeutically active compounds and their methods of use 11 Jul, 2034
Active
US9474779 Therapeutically active compositions and their methods of use 19 Aug, 2033
Active
US10717764 Therapeutically active compounds and their methods of use 18 Jan, 2033
Active
US11667673 Therapeutically active compounds and their methods of use 18 Jan, 2033
Active
US9850277 Therapeutically active compositions and their methods of use 18 Jan, 2033
Active
US10610125 Methods and compositions for cell-proliferation-related disorders 21 Jun, 2030
Active


Given below is the list of recent legal activities going on the following drug patents of Servier.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 25 Apr, 2024 US9474779
Payment of Maintenance Fee, 4th Year, Large Entity 22 Jan, 2024 US10717764
Payment of Maintenance Fee, 4th Year, Large Entity 20 Nov, 2023 US10653710
Electronic Review 06 Jun, 2023 US11667673
Mail Patent eGrant Notification 06 Jun, 2023 US11667673
Recordation of Patent eGrant 06 Jun, 2023 US11667673
Patent Issue Date Used in PTA Calculation 06 Jun, 2023 US11667673
Recordation of Patent Grant Mailed 06 Jun, 2023 US11667673
Email Notification 06 Jun, 2023 US11667673
Patent eGrant Notification 06 Jun, 2023 US11667673
Electronic Review 18 May, 2023 US11667673
Email Notification 18 May, 2023 US11667673
Issue Notification Mailed 17 May, 2023 US11667673
Dispatch to FDC 25 Apr, 2023 US11667673
Application Is Considered Ready for Issue 25 Apr, 2023 US11667673


Servier's Drug Patent Litigations

Servier's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 15, 2022, against patent number US10610125. The petitioner Rigel Pharmaceuticals, Inc., challenged the validity of this patent, with Servier Pharmaceuticals LLC et al. as the respondent. Click below to track the latest information on how companies are challenging Servier's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10610125 August, 2022 Terminated-Settled
(06 Jan, 2023)
Servier Pharmaceuticals LLC et al. Rigel Pharmaceuticals, Inc.


Servier's Family Patents

Servier drugs have patent protection in a total of 39 countries. It's US patent count contributes only to 22.3% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Servier Drug List

Given below is the complete list of Servier's drugs and the patents protecting them.


1. Tibsovo

Tibsovo is protected by 10 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10980788 Therapy for treating malignancies 07 Jun, 2039
(14 years from now)
Active
US10653710 Combination therapy for treating malignancies 18 Oct, 2036
(12 years from now)
Active
US10449184 Pharmaceutical compositions of therapeutically active compounds 13 Mar, 2035
(10 years from now)
Active
US10799490 Pharmaceutical compositions of therapeutically active compounds 13 Mar, 2035
(10 years from now)
Active
US9968595 Pharmaceutical compositions of therapeutically active compounds 13 Mar, 2035
(10 years from now)
Active
US9474779 Therapeutically active compositions and their methods of use 19 Aug, 2033
(8 years from now)
Active
US10717764 Therapeutically active compounds and their methods of use 18 Jan, 2033
(8 years from now)
Active
US11667673 Therapeutically active compounds and their methods of use 18 Jan, 2033
(8 years from now)
Active
US9850277 Therapeutically active compositions and their methods of use 18 Jan, 2033
(8 years from now)
Active
US10610125 Methods and compositions for cell-proliferation-related disorders 21 Jun, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tibsovo's drug page


2. Voranigo

Voranigo is protected by 4 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11345677 Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same 16 Jan, 2039
(14 years from now)
Active
US11844758 Therapeutically active compounds and their methods of use 04 Dec, 2035
(11 years from now)
Active
US10172864 Therapeutically active compounds and their methods of use 11 Jul, 2034
(9 years from now)
Active
US9579324 Therapeutically active compounds and their methods of use 11 Jul, 2034
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Voranigo's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Servier News

FDA Approves First-In-Class Treatment for Two Types after Servier's Successful Acquisition

07 Aug, 2024

See More